Non-interventional Study to Assess the Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma (FL)
Phase of Trial: Phase IV
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Idelalisib (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions
- Acronyms ZEUS
- Sponsors Gilead Sciences
- 10 Jun 2019 Planned End Date changed from 1 Nov 2020 to 1 Oct 2020.
- 10 Jun 2019 Planned primary completion date changed from 1 May 2019 to 1 Oct 2020.
- 02 Jul 2018 New trial record